Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2019 pp 997–1007Cite as

Urologika

  • Chapter
  • First Online:

  • 2848 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Literatur

  • Alhasso AA, McKinlay J, Patrick K, Stewart L (2006) Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; (4): CD003193

    Google Scholar 

  • Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmastser R (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–1202

    Article  CAS  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2018) Mögliche Risiken bei der Anwendung finasteridhaltiger Arzneimittel (1 mg und 5 mg Dosierung) sowie Empfehlungen zur Aufklärung Ihrer Patienten. https://www.akdae.de/Arzneimittelsicherheit/RHB/index.html

    Google Scholar 

  • Boyle P, Gould AL, Roehrborn CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48:398–405

    Article  CAS  Google Scholar 

  • Bundesministerium für Gesundheit (2015): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage IX – Festbetragsgruppenbildung Anlage X – Aktualisierung von Vergleichsgrößen, Urologische Spasmolytika, Gruppe 1, in Stufe 3 nach § 35 Absatz 1 des Fünften Buches Sozialgesetzbuch (SGB V) vom 15. Oktober 2015 veröffentlicht am Mittwoch, 2. Dezember 2015 BAnz AT 2. Dez. 2015 B2

    Google Scholar 

  • Chapple CR (1996) Selective a1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 29:129–144

    CAS  PubMed  Google Scholar 

  • Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A, YM-905 Study Group (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Brit J Urol Int 93:303–310

    Article  CAS  Google Scholar 

  • Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E, European Silodosin Study Group (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 59:342–352

    Article  CAS  Google Scholar 

  • Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N (2013) Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63:296–305

    Article  CAS  Google Scholar 

  • Djavan B, Marberger M (1999) A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36:1–13

    Article  CAS  Google Scholar 

  • Gemeinsamer Bundesausschuss (2014) Beschlusstext Mirabegron. https://www.g-ba.de/downloads/39-261-2099/2014-11-20_AM-RL-XII_Mirabegron_2014-06-01-D-110_BAnz.pdf

    Google Scholar 

  • Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, Rieken M, Speakman MJ, Tikkinen KAO and Guidelines Associates: Karavitakis M, Kyriazis I, Malde S, Sakalis V, Umbach R. EAU Guidelines. Edn. presented at the EAU Annual Congress Barcelona 2019. ISBN 978-94-92671-04-2. EAU Guidelines Office, Arnhem, The Netherlands. http://uroweb.org/guidelines/compilations-of-all-guidelines/

  • Grünewald V (2005) Pharmakologische Therapie von neurogenen Harnblasenfunktionsstörungen. In: Truß MC et al (Hrsg) Pharmakotherapie in der Urologie. Springer, Heidelberg, S 383–311

    Google Scholar 

  • Haab F, Stewart L, Dwyer P (2004) Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45:420–429

    Article  CAS  Google Scholar 

  • Harvey M-A, Baker K, Wells GA (2003) Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 185:56–61

    Article  Google Scholar 

  • Hay-Smith J, Herbison P, Ellis G, Morris A (2005) Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005; (3): CD005429

    Google Scholar 

  • Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB, Prospective European Doxazosin and Combination Therapy Study Investigators (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European Doxazosin and combination therapy (PRE-DICT) trial. Urology 61:119–126

    Article  Google Scholar 

  • Madersbacher H, Halaska M, Voigt R, Alloussi S, Höfner K (1999) A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84:646–651

    Article  CAS  Google Scholar 

  • Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ (2012) Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012 Jan 18; (1): CD005429

    Google Scholar 

  • McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398

    Article  CAS  Google Scholar 

  • Milani S, Djavan B (2005) Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 95(Suppl 4):29–36

    Article  CAS  Google Scholar 

  • Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC, Duloxetine UI Study Group (2004) Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. Brit J Urol Int 93:311–318

    Article  CAS  Google Scholar 

  • Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; (4): CD003781

    Google Scholar 

  • Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS (2011) Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the enlarged prostate international Comparator study (EPICS). BJU Int 108:388–394

    Article  CAS  Google Scholar 

  • Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, CombAT Study Group (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57:123–131

    Article  CAS  Google Scholar 

  • Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan BA, Szczepanek CM, Ceowley JJ, Coltman CA (2003) The Influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224

    Article  CAS  Google Scholar 

  • Thüroff JW, Chartier-Kastler E, Corcus J, Humke J, Jonas U, Palmtag H, Tanagho EA (1998) Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 16(suppl):S48–S61

    Article  Google Scholar 

  • Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M (2015) Adverse effects of 5α-reductase inhibitors: what do we know, don’t know, and need to know? Rev Endocr Metab Disord 16:177–198

    Article  CAS  Google Scholar 

  • Tsujii T (2000) Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. Int J Urol 7:199–205

    Article  CAS  Google Scholar 

  • Woodford HJ (2018) Anticholinergic drugs for overactive bladder in frail older patients: The case against. Drugs Aging 35:773–776

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Pharmakologie, Bremen, Deutschland

    Prof. Dr. med. Bernd Mühlbauer

  2. Emmendingen, Deutschland

    Prof. Dr. med. Hartmut Oßwald

Authors
  1. Prof. Dr. med. Bernd Mühlbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Hartmut Oßwald
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernd Mühlbauer .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Ulrich Schwabe

  2. Köln, Nordrhein-Westfalen, Germany

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ), Berlin, Berlin, Germany

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK, Berlin, Berlin, Germany

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mühlbauer, B., Oßwald, H. (2019). Urologika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2019. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-59046-1_45

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-59046-1_45

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-59045-4

  • Online ISBN: 978-3-662-59046-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation